Anti-cancer biotech company Prescient Therapeutics (PTX) has received two key licences to build a new cell therapy platform. Prescient revealed today it has received an…

It is impossible to overstate the unprecedented disruptions the world is facing with COVID-19. Stock markets have plunged worldwide and our healthcare system is overworked….

AFL player Ben Brown recently shared a story about his cousin Grace’s battle with cancer, imploring people to stay home during the pandemic to protect…

Cancer is the leading cause of death in Australia, claiming almost 50,000 lives in 2019. The most common treatments for cancer include chemo and radiation…

When you think of cancer therapies, you may automatically think of chemo and radiation. While those are highly effective at putting certain cancers into remission,…

Personalised medicine seems to be the way of the future; where patients receive tailored treatments to suit their individual needs and biometric traits. Medicine and…

Revolution Medicines has filed to raise $100 million in an IPO. The anticipated fundraising haul will bankroll development of a pipeline of RAS programs up to the…

Cancer has been on the public radar for many years now and, although several drugs exist to treat the disease, none of them are effective…

Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the…

We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The drivers to our valuation chance include: (1) adjustment to base…